Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Monday, November 23, 2009, 7:24PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
PERSONAL FINANCE
SMALL BUSINESS
Enter symbol(s):
Symbol Lookup
|
Exchanges
Search News:
Gilead Sciences Inc. (GILD)
On Nov 21:
46.39 USD
0.00 (0.00%)
MORE ON GILD
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
Technical Analysis
Detailed Data
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Gilead Sciences, Inc.
(NasdaqNM:GILD) Delayed quote data
Last Trade:
46.39 USD
Trade Time:
Nov 21
Change:
0.00 (0.00%)
Prev Close:
46.39
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
55.61
Day's Range:
N/A - N/A
52wk Range:
39.37 - 53.28
Volume:
0
Avg Vol
(3m)
:
7,511,880
Market Cap:
41.75B
P/E
(ttm)
:
17.94
EPS
(ttm)
:
2.59
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add GILD to Portfolio
Download Data
HEADLINES
The Highest Possible Returns. Period.
at Motley Fool
(Mon 12:00AM)
UPDATE - UK investigates spread of drug resistant swine flu
at Reuters
(Sat, Nov 21)
J&J stays true to its diversified model
at FT.com
(Sat, Nov 21)
Ten Minutes That Mattered: Gilead's Martin
at Forbes.com
(Fri, Nov 20)
5 Stocks Geared for Growth
at Motley Fool
(Fri, Nov 20)
Now's a Great Time to Invest -- So Don't Blow It Like This
at Motley Fool
(Fri, Nov 20)
5 Stocks Making Cash
at Motley Fool
(Thu, Nov 19)
Connor Browne: Asset Allocation Is Key in Current Environment
at Seeking Alpha
(Thu, Nov 19)
A Big Upgrade for Sanofi-Aventis
at Motley Fool
(Wed, Nov 18)
The Worst Stocks to Buy Today
at Motley Fool
(Tue, Nov 17)
The Hottest Sector for 2010
at Motley Fool
(Tue, Nov 17)
More Headlines for GILD...
ANALYST
EPS Est (next year)
(Dec-09)
:
2.76
EPS Est (in 2 years)
(Dec-10)
:
3.13
Avg Rec (current)*:
1.8
PEG Ratio:
1.09
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Australia
New Zealand
US
----------------
Argentina
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Malaysia
Mexico
Netherlands
Norway
Singapore
South Korea - Korea
South Korea - KOSDAQ
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Symbol Lookup
Latest News
7 Indices